Association between P16(INK4a) Promoter Methylation and Ovarian Cancer: A Meta-Analysis of 12 Published Studies

BACKGROUND: Ovarian cancer is the primary cause of death in women diagnosed with gynecological malignancies worldwide. Absence of early symptoms prevents prompt diagnosis or successful therapeutic intervention. P16(INK4a) is a well-known tumor suppressor gene (TSG). Aberrant methylation of TSG promoter is an important epigenetic silencing mechanism leading to ovarian cancer progression. Studies have reported differences in methylation frequencies of the p16(INK4a) promoter between ovarian cancer and the corresponding control group. However, the association between p16(INK4a) promoter methylation and ovarian cancer remains unclear and controversial. Therefore, a meta-analysis was conducted to clarify the relationship between p16(INK4a) promoter methylation and ovarian cancer. METHODS: PubMed, Web of Science, EMBASE and CNKI were searched to identify eligible studies for the evaluation of the association between p16(INK4a) promoter methylation and ovarian cancer. Odds ratio (ORs) and 95% confidence intervals (95%CI) were calculated to determine the strength of association between p16(INK4a) promoter methylation and ovarian cancer. RESULTS: A total of 612 ovarian cancer patients and 289 controls from 12 eligible studies were included in the meta-analysis. Overall, a significant association was observed between p16(INK4a) methylation status and ovarian cancer risk using a fixed-effects model (OR = 2.02, 95% CI = 1.39–2.94). CONCLUSION: The results of our meta-analysis show that aberrant methylation of p16(INK4a) promoter was significantly associated with ovarian cancer. It may represent a promising molecular marker to monitor the disease and provides new insights into the treatment of human ovarian cancer.